Patient and graft characteristics
| Characteristic . | n (%) . |
|---|---|
| Sex | |
| Male | 8 (36) |
| Female | 14 (64) |
| Diagnosis | |
| ALL Ph+ [CR1/ ≥ CR2] | 14 [10/4] (64) |
| ALL B-lineage | 6 (27) |
| ALL T-lineage | 2 (9) |
| Disease status at transplantation | |
| CR1 | 12 (55) |
| CR2 or greater | 9 (40) |
| PIF-sensitive | 1 (5) |
| CNS disease at diagnosis | |
| No | 16 (73) |
| Yes [cranial irradiation Y/N] | 6 [1/5] (27) |
| Prior autotransplantation/allotransplantation | |
| None | 19 (86) |
| Yes, autotransplantation | 2 (9) |
| Yes, allotransplantation | 1 (5) |
| Induction/intensification therapy (CR1 patients) | 12 (55) |
| Hyper-CVAD /M, Ara-C, P | 2 (9) |
| Da, V, C, L-asp, P/C, Ara-C, 6MP, V, L-asp | 4 (18) |
| Da, V, L-asp, P/C, Ara-C, 6MP | 5 (21) |
| Unknown | 1 (5) |
| Recipient CMV | |
| Negative | 9 (41) |
| Positive | 13 (59) |
| Donor CMV | |
| Negative | 14 (77) |
| Positive | 5 (23) |
| Year of transplantation | |
| 2001-2004 | 10 (47) |
| 2005-2008 | 12 (53) |
| Donor type (HLA locus matching) | |
| PBSC sibling (6 of 6) | 4 (18) |
| UCB (4 of 6) | 12 (55) |
| UCB (5 of 6) | 5 (23) |
| UCB (6 of 6) | 1 (5) |
| Comorbidity index | |
| 0 | 6 (36) |
| 1-2 | 4 (18) |
| 3 or higher | 11 (55) |
| Median (range) | 3 (0–8) |
| Median WBC at diagnosis | 20 (range, 1.4-248) |
| Weight, kg | 74.8 (range, 41.5-120) |
| Follow-up, mo | 33 (range, 5-76) |
| Characteristic . | n (%) . |
|---|---|
| Sex | |
| Male | 8 (36) |
| Female | 14 (64) |
| Diagnosis | |
| ALL Ph+ [CR1/ ≥ CR2] | 14 [10/4] (64) |
| ALL B-lineage | 6 (27) |
| ALL T-lineage | 2 (9) |
| Disease status at transplantation | |
| CR1 | 12 (55) |
| CR2 or greater | 9 (40) |
| PIF-sensitive | 1 (5) |
| CNS disease at diagnosis | |
| No | 16 (73) |
| Yes [cranial irradiation Y/N] | 6 [1/5] (27) |
| Prior autotransplantation/allotransplantation | |
| None | 19 (86) |
| Yes, autotransplantation | 2 (9) |
| Yes, allotransplantation | 1 (5) |
| Induction/intensification therapy (CR1 patients) | 12 (55) |
| Hyper-CVAD /M, Ara-C, P | 2 (9) |
| Da, V, C, L-asp, P/C, Ara-C, 6MP, V, L-asp | 4 (18) |
| Da, V, L-asp, P/C, Ara-C, 6MP | 5 (21) |
| Unknown | 1 (5) |
| Recipient CMV | |
| Negative | 9 (41) |
| Positive | 13 (59) |
| Donor CMV | |
| Negative | 14 (77) |
| Positive | 5 (23) |
| Year of transplantation | |
| 2001-2004 | 10 (47) |
| 2005-2008 | 12 (53) |
| Donor type (HLA locus matching) | |
| PBSC sibling (6 of 6) | 4 (18) |
| UCB (4 of 6) | 12 (55) |
| UCB (5 of 6) | 5 (23) |
| UCB (6 of 6) | 1 (5) |
| Comorbidity index | |
| 0 | 6 (36) |
| 1-2 | 4 (18) |
| 3 or higher | 11 (55) |
| Median (range) | 3 (0–8) |
| Median WBC at diagnosis | 20 (range, 1.4-248) |
| Weight, kg | 74.8 (range, 41.5-120) |
| Follow-up, mo | 33 (range, 5-76) |
ALL indicates acute lymphoblastic leukemia; Ph+, Philadelphia chromosome–positive; CR, complete remission; PIF, primary induction failure; C, cyclophosphamide; V, vincristine; A, doxorubicin; Ara-C, cytarabine; 6MP, 6-mercaptopurine; Da, daunorubicin; D, dexamethasone; P, prednisone; L-asp, L-asparaginase; M, methotrexate; CMV, cytomegalovirus; WBC, white blood cell count; HLA, human leukocyte antigen; PBSC, peripheral blood stem cell; and UCB, umbilical cord blood.